NCT03761017: MGD019 DART Protein in Unresectable/Metastatic Cancer

NCT03761017
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated symptomatic CNS metastases or concurrent leptomeningeal disease – see trial for details; Patients who have received prior therapy with a combination of monoclonal antibodies against PD-1/PD-L1 & CTLA-4 will be excluded in the Cohort Expansion
https://ClinicalTrials.gov/show/NCT03761017

Comments are closed.

Up ↑